Global Bulimia Nervosa Treatment Market
Global Bulimia Nervosa Treatment Market

Bulimia Nervosa Treatment Comprehensive Study by Therapy (Support group, Cognitive behavioral therapy, Cognitive therapy, Diaelectical behavior therapy, Counseling psychology, Family therapy, Others), Drug type (Antidepressants, Antipsychotics, Others), Route of administration (Oral, Intravenous, Others), End user (Hospitals and Clinics, Home care Settings, Specialty Centers, Others), Disorder type (Purging, Non-Purging) Players and Region - Global Market Outlook to 2025

Bulimia Nervosa Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Apr 2020 Edition 209 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Bulimia is an eating disorder which allows people to binge eat. Then, the individual takes steps for weight loss which includes excessive exercising. The treatment of bulimia nervosa includes counseling, medication and nutrition education. This disease can last a year or lifelong. It is elf diagnosed and treated by medical professionals. However, the lab tests are rarely required. Moreover, the treatment includes various therapies and drugs such as antipsychotic and others.

The market study is being classified and major geographies with country level break-up.

Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Forest Pharmaceuticals, Inc. (United States), Pfizer, Inc. (United States), Bristol-Myers Squibb (United States), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Allergan, Inc. (Ireland), Dr. Reddy’s Laboratories Limited (India) and Lupin Pharmaceuticals, Inc. (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Aurobindo Pharma (India), Zydus Cadila (India), Apotex Inc. (Canada), Teva Pharmaceutical Industries Ltd (Israel) and Sun Pharmaceutical Industries Ltd (India).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Bulimia Nervosa Treatment market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Bulimia Nervosa Treatment market by Type, Application and Region.

On the basis of geography, the market of Bulimia Nervosa Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Cardiovascular Diseases is leading to Bulimia Nervosa
  • Increasing Intake of Alcohol Is Leading to This Disease which is fueling the Market Growth

Market Trend
  • Decreasing Effect of these Disease in Younger Generation due to the Adoption of Healthy Eating

Restraints
  • High Costs Associated with the Treatment
  • Lack of Specific Drugs for the Treatment of Bulimia Nervosa

Opportunities
  • Developments of Healthcare Infrastructure
  • Government Initiatives towards Healthcare

Challenges
  • Lack of Awareness among the People


Market Leaders and their expansionary development strategies
On 17th June 2019, Pfizer has acquired Array biopharma which is focused on development and commercialization of small molecule drugs.



Key Target Audience
Drug Manufacturers, Raw material suppliers, Government associations, Research organizations, Enterprise software vendors and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Therapy
  • Support group
  • Cognitive behavioral therapy
  • Cognitive therapy
  • Diaelectical behavior therapy
  • Counseling psychology
  • Family therapy
  • Others

By Drug type
  • Antidepressants
  • Antipsychotics
  • Others

By Route of administration
  • Oral
  • Intravenous
  • Others

By End user
  • Hospitals and Clinics
  • Home care Settings
  • Specialty Centers
  • Others

By Disorder type
  • Purging
  • Non-Purging

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cardiovascular Diseases is leading to Bulimia Nervosa
      • 3.2.2. Increasing Intake of Alcohol Is Leading to This Disease which is fueling the Market Growth
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the People
    • 3.4. Market Trends
      • 3.4.1. Decreasing Effect of these Disease in Younger Generation due to the Adoption of Healthy Eating
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bulimia Nervosa Treatment, by Therapy, Drug type, Route of administration, End user, Disorder type and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Bulimia Nervosa Treatment (Value)
      • 5.2.1. Global Bulimia Nervosa Treatment by: Therapy (Value)
        • 5.2.1.1. Support group
        • 5.2.1.2. Cognitive behavioral therapy
        • 5.2.1.3. Cognitive therapy
        • 5.2.1.4. Diaelectical behavior therapy
        • 5.2.1.5. Counseling psychology
        • 5.2.1.6. Family therapy
        • 5.2.1.7. Others
      • 5.2.2. Global Bulimia Nervosa Treatment by: Drug type (Value)
        • 5.2.2.1. Antidepressants
        • 5.2.2.2. Antipsychotics
        • 5.2.2.3. Others
      • 5.2.3. Global Bulimia Nervosa Treatment by: Route of administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous
        • 5.2.3.3. Others
      • 5.2.4. Global Bulimia Nervosa Treatment by: End user (Value)
        • 5.2.4.1. Hospitals and Clinics
        • 5.2.4.2. Home care Settings
        • 5.2.4.3. Specialty Centers
        • 5.2.4.4. Others
      • 5.2.5. Global Bulimia Nervosa Treatment by: Disorder type (Value)
        • 5.2.5.1. Purging
        • 5.2.5.2. Non-Purging
      • 5.2.6. Global Bulimia Nervosa Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Bulimia Nervosa Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Forest Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan, Inc. (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dr. Reddy’s Laboratories Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lupin Pharmaceuticals, Inc. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bulimia Nervosa Treatment Sale, by Therapy, Drug type, Route of administration, End user, Disorder type and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Bulimia Nervosa Treatment (Value)
      • 7.2.1. Global Bulimia Nervosa Treatment by: Therapy (Value)
        • 7.2.1.1. Support group
        • 7.2.1.2. Cognitive behavioral therapy
        • 7.2.1.3. Cognitive therapy
        • 7.2.1.4. Diaelectical behavior therapy
        • 7.2.1.5. Counseling psychology
        • 7.2.1.6. Family therapy
        • 7.2.1.7. Others
      • 7.2.2. Global Bulimia Nervosa Treatment by: Drug type (Value)
        • 7.2.2.1. Antidepressants
        • 7.2.2.2. Antipsychotics
        • 7.2.2.3. Others
      • 7.2.3. Global Bulimia Nervosa Treatment by: Route of administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous
        • 7.2.3.3. Others
      • 7.2.4. Global Bulimia Nervosa Treatment by: End user (Value)
        • 7.2.4.1. Hospitals and Clinics
        • 7.2.4.2. Home care Settings
        • 7.2.4.3. Specialty Centers
        • 7.2.4.4. Others
      • 7.2.5. Global Bulimia Nervosa Treatment by: Disorder type (Value)
        • 7.2.5.1. Purging
        • 7.2.5.2. Non-Purging
      • 7.2.6. Global Bulimia Nervosa Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bulimia Nervosa Treatment: by Therapy(USD Million)
  • Table 2. Bulimia Nervosa Treatment Support group , by Region USD Million (2014-2019)
  • Table 3. Bulimia Nervosa Treatment Cognitive behavioral therapy , by Region USD Million (2014-2019)
  • Table 4. Bulimia Nervosa Treatment Cognitive therapy , by Region USD Million (2014-2019)
  • Table 5. Bulimia Nervosa Treatment Diaelectical behavior therapy , by Region USD Million (2014-2019)
  • Table 6. Bulimia Nervosa Treatment Counseling psychology , by Region USD Million (2014-2019)
  • Table 7. Bulimia Nervosa Treatment Family therapy , by Region USD Million (2014-2019)
  • Table 8. Bulimia Nervosa Treatment Others , by Region USD Million (2014-2019)
  • Table 9. Bulimia Nervosa Treatment: by Drug type(USD Million)
  • Table 10. Bulimia Nervosa Treatment Antidepressants , by Region USD Million (2014-2019)
  • Table 11. Bulimia Nervosa Treatment Antipsychotics , by Region USD Million (2014-2019)
  • Table 12. Bulimia Nervosa Treatment Others , by Region USD Million (2014-2019)
  • Table 13. Bulimia Nervosa Treatment: by Route of administration(USD Million)
  • Table 14. Bulimia Nervosa Treatment Oral , by Region USD Million (2014-2019)
  • Table 15. Bulimia Nervosa Treatment Intravenous , by Region USD Million (2014-2019)
  • Table 16. Bulimia Nervosa Treatment Others , by Region USD Million (2014-2019)
  • Table 17. Bulimia Nervosa Treatment: by End user(USD Million)
  • Table 18. Bulimia Nervosa Treatment Hospitals and Clinics , by Region USD Million (2014-2019)
  • Table 19. Bulimia Nervosa Treatment Home care Settings , by Region USD Million (2014-2019)
  • Table 20. Bulimia Nervosa Treatment Specialty Centers , by Region USD Million (2014-2019)
  • Table 21. Bulimia Nervosa Treatment Others , by Region USD Million (2014-2019)
  • Table 22. Bulimia Nervosa Treatment: by Disorder type(USD Million)
  • Table 23. Bulimia Nervosa Treatment Purging , by Region USD Million (2014-2019)
  • Table 24. Bulimia Nervosa Treatment Non-Purging , by Region USD Million (2014-2019)
  • Table 25. South America Bulimia Nervosa Treatment, by Country USD Million (2014-2019)
  • Table 26. South America Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 27. South America Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 28. South America Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 29. South America Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 30. South America Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 31. Brazil Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 32. Brazil Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 33. Brazil Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 34. Brazil Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 35. Brazil Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 36. Argentina Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 37. Argentina Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 38. Argentina Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 39. Argentina Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 40. Argentina Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 41. Rest of South America Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 42. Rest of South America Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 43. Rest of South America Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 44. Rest of South America Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 45. Rest of South America Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 46. Asia Pacific Bulimia Nervosa Treatment, by Country USD Million (2014-2019)
  • Table 47. Asia Pacific Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 48. Asia Pacific Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 49. Asia Pacific Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 50. Asia Pacific Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 51. Asia Pacific Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 52. China Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 53. China Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 54. China Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 55. China Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 56. China Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 57. Japan Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 58. Japan Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 59. Japan Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 60. Japan Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 61. Japan Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 62. India Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 63. India Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 64. India Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 65. India Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 66. India Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 67. South Korea Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 68. South Korea Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 69. South Korea Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 70. South Korea Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 71. South Korea Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 72. Taiwan Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 73. Taiwan Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 74. Taiwan Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 75. Taiwan Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 76. Taiwan Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 77. Australia Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 78. Australia Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 79. Australia Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 80. Australia Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 81. Australia Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 82. Rest of Asia-Pacific Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 83. Rest of Asia-Pacific Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 84. Rest of Asia-Pacific Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 85. Rest of Asia-Pacific Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 86. Rest of Asia-Pacific Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 87. Europe Bulimia Nervosa Treatment, by Country USD Million (2014-2019)
  • Table 88. Europe Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 89. Europe Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 90. Europe Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 91. Europe Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 92. Europe Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 93. Germany Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 94. Germany Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 95. Germany Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 96. Germany Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 97. Germany Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 98. France Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 99. France Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 100. France Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 101. France Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 102. France Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 103. Italy Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 104. Italy Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 105. Italy Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 106. Italy Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 107. Italy Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 108. United Kingdom Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 109. United Kingdom Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 110. United Kingdom Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 111. United Kingdom Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 112. United Kingdom Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 113. Netherlands Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 114. Netherlands Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 115. Netherlands Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 116. Netherlands Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 117. Netherlands Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 118. Rest of Europe Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 119. Rest of Europe Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 120. Rest of Europe Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 121. Rest of Europe Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 122. Rest of Europe Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 123. MEA Bulimia Nervosa Treatment, by Country USD Million (2014-2019)
  • Table 124. MEA Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 125. MEA Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 126. MEA Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 127. MEA Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 128. MEA Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 129. Middle East Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 130. Middle East Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 131. Middle East Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 132. Middle East Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 133. Middle East Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 134. Africa Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 135. Africa Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 136. Africa Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 137. Africa Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 138. Africa Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 139. North America Bulimia Nervosa Treatment, by Country USD Million (2014-2019)
  • Table 140. North America Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 141. North America Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 142. North America Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 143. North America Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 144. North America Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 145. United States Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 146. United States Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 147. United States Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 148. United States Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 149. United States Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 150. Canada Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 151. Canada Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 152. Canada Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 153. Canada Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 154. Canada Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 155. Mexico Bulimia Nervosa Treatment, by Therapy USD Million (2014-2019)
  • Table 156. Mexico Bulimia Nervosa Treatment, by Drug type USD Million (2014-2019)
  • Table 157. Mexico Bulimia Nervosa Treatment, by Route of administration USD Million (2014-2019)
  • Table 158. Mexico Bulimia Nervosa Treatment, by End user USD Million (2014-2019)
  • Table 159. Mexico Bulimia Nervosa Treatment, by Disorder type USD Million (2014-2019)
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Bulimia Nervosa Treatment: by Therapy(USD Million)
  • Table 171. Bulimia Nervosa Treatment Support group , by Region USD Million (2020-2025)
  • Table 172. Bulimia Nervosa Treatment Cognitive behavioral therapy , by Region USD Million (2020-2025)
  • Table 173. Bulimia Nervosa Treatment Cognitive therapy , by Region USD Million (2020-2025)
  • Table 174. Bulimia Nervosa Treatment Diaelectical behavior therapy , by Region USD Million (2020-2025)
  • Table 175. Bulimia Nervosa Treatment Counseling psychology , by Region USD Million (2020-2025)
  • Table 176. Bulimia Nervosa Treatment Family therapy , by Region USD Million (2020-2025)
  • Table 177. Bulimia Nervosa Treatment Others , by Region USD Million (2020-2025)
  • Table 178. Bulimia Nervosa Treatment: by Drug type(USD Million)
  • Table 179. Bulimia Nervosa Treatment Antidepressants , by Region USD Million (2020-2025)
  • Table 180. Bulimia Nervosa Treatment Antipsychotics , by Region USD Million (2020-2025)
  • Table 181. Bulimia Nervosa Treatment Others , by Region USD Million (2020-2025)
  • Table 182. Bulimia Nervosa Treatment: by Route of administration(USD Million)
  • Table 183. Bulimia Nervosa Treatment Oral , by Region USD Million (2020-2025)
  • Table 184. Bulimia Nervosa Treatment Intravenous , by Region USD Million (2020-2025)
  • Table 185. Bulimia Nervosa Treatment Others , by Region USD Million (2020-2025)
  • Table 186. Bulimia Nervosa Treatment: by End user(USD Million)
  • Table 187. Bulimia Nervosa Treatment Hospitals and Clinics , by Region USD Million (2020-2025)
  • Table 188. Bulimia Nervosa Treatment Home care Settings , by Region USD Million (2020-2025)
  • Table 189. Bulimia Nervosa Treatment Specialty Centers , by Region USD Million (2020-2025)
  • Table 190. Bulimia Nervosa Treatment Others , by Region USD Million (2020-2025)
  • Table 191. Bulimia Nervosa Treatment: by Disorder type(USD Million)
  • Table 192. Bulimia Nervosa Treatment Purging , by Region USD Million (2020-2025)
  • Table 193. Bulimia Nervosa Treatment Non-Purging , by Region USD Million (2020-2025)
  • Table 194. South America Bulimia Nervosa Treatment, by Country USD Million (2020-2025)
  • Table 195. South America Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 196. South America Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 197. South America Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 198. South America Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 199. South America Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 200. Brazil Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 201. Brazil Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 202. Brazil Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 203. Brazil Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 204. Brazil Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 205. Argentina Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 206. Argentina Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 207. Argentina Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 208. Argentina Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 209. Argentina Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 210. Rest of South America Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 211. Rest of South America Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 212. Rest of South America Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 213. Rest of South America Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 214. Rest of South America Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 215. Asia Pacific Bulimia Nervosa Treatment, by Country USD Million (2020-2025)
  • Table 216. Asia Pacific Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 217. Asia Pacific Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 218. Asia Pacific Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 219. Asia Pacific Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 220. Asia Pacific Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 221. China Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 222. China Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 223. China Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 224. China Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 225. China Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 226. Japan Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 227. Japan Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 228. Japan Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 229. Japan Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 230. Japan Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 231. India Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 232. India Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 233. India Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 234. India Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 235. India Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 236. South Korea Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 237. South Korea Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 238. South Korea Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 239. South Korea Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 240. South Korea Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 241. Taiwan Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 242. Taiwan Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 243. Taiwan Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 244. Taiwan Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 245. Taiwan Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 246. Australia Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 247. Australia Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 248. Australia Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 249. Australia Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 250. Australia Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 251. Rest of Asia-Pacific Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 252. Rest of Asia-Pacific Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 253. Rest of Asia-Pacific Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 254. Rest of Asia-Pacific Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 255. Rest of Asia-Pacific Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 256. Europe Bulimia Nervosa Treatment, by Country USD Million (2020-2025)
  • Table 257. Europe Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 258. Europe Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 259. Europe Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 260. Europe Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 261. Europe Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 262. Germany Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 263. Germany Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 264. Germany Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 265. Germany Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 266. Germany Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 267. France Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 268. France Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 269. France Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 270. France Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 271. France Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 272. Italy Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 273. Italy Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 274. Italy Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 275. Italy Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 276. Italy Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 277. United Kingdom Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 278. United Kingdom Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 279. United Kingdom Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 280. United Kingdom Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 281. United Kingdom Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 282. Netherlands Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 283. Netherlands Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 284. Netherlands Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 285. Netherlands Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 286. Netherlands Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 287. Rest of Europe Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 288. Rest of Europe Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 289. Rest of Europe Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 290. Rest of Europe Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 291. Rest of Europe Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 292. MEA Bulimia Nervosa Treatment, by Country USD Million (2020-2025)
  • Table 293. MEA Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 294. MEA Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 295. MEA Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 296. MEA Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 297. MEA Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 298. Middle East Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 299. Middle East Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 300. Middle East Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 301. Middle East Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 302. Middle East Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 303. Africa Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 304. Africa Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 305. Africa Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 306. Africa Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 307. Africa Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 308. North America Bulimia Nervosa Treatment, by Country USD Million (2020-2025)
  • Table 309. North America Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 310. North America Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 311. North America Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 312. North America Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 313. North America Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 314. United States Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 315. United States Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 316. United States Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 317. United States Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 318. United States Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 319. Canada Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 320. Canada Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 321. Canada Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 322. Canada Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 323. Canada Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 324. Mexico Bulimia Nervosa Treatment, by Therapy USD Million (2020-2025)
  • Table 325. Mexico Bulimia Nervosa Treatment, by Drug type USD Million (2020-2025)
  • Table 326. Mexico Bulimia Nervosa Treatment, by Route of administration USD Million (2020-2025)
  • Table 327. Mexico Bulimia Nervosa Treatment, by End user USD Million (2020-2025)
  • Table 328. Mexico Bulimia Nervosa Treatment, by Disorder type USD Million (2020-2025)
  • Table 329. Research Programs/Design for This Report
  • Table 330. Key Data Information from Secondary Sources
  • Table 331. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bulimia Nervosa Treatment: by Therapy USD Million (2014-2019)
  • Figure 5. Global Bulimia Nervosa Treatment: by Drug type USD Million (2014-2019)
  • Figure 6. Global Bulimia Nervosa Treatment: by Route of administration USD Million (2014-2019)
  • Figure 7. Global Bulimia Nervosa Treatment: by End user USD Million (2014-2019)
  • Figure 8. Global Bulimia Nervosa Treatment: by Disorder type USD Million (2014-2019)
  • Figure 9. South America Bulimia Nervosa Treatment Share (%), by Country
  • Figure 10. Asia Pacific Bulimia Nervosa Treatment Share (%), by Country
  • Figure 11. Europe Bulimia Nervosa Treatment Share (%), by Country
  • Figure 12. MEA Bulimia Nervosa Treatment Share (%), by Country
  • Figure 13. North America Bulimia Nervosa Treatment Share (%), by Country
  • Figure 14. Global Bulimia Nervosa Treatment share by Players 2019 (%)
  • Figure 15. Global Bulimia Nervosa Treatment share by Players (Top 3) 2019(%)
  • Figure 16. Global Bulimia Nervosa Treatment share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 20. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. AstraZeneca (United Kingdom) Revenue: by Geography 2019
  • Figure 22. Forest Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Forest Pharmaceuticals, Inc. (United States) Revenue: by Geography 2019
  • Figure 24. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer, Inc. (United States) Revenue: by Geography 2019
  • Figure 26. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol-Myers Squibb (United States) Revenue: by Geography 2019
  • Figure 28. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 29. Johnson & Johnson (United States) Revenue: by Geography 2019
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2019
  • Figure 32. Allergan, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 33. Allergan, Inc. (Ireland) Revenue: by Geography 2019
  • Figure 34. Dr. Reddy’s Laboratories Limited (India) Revenue, Net Income and Gross profit
  • Figure 35. Dr. Reddy’s Laboratories Limited (India) Revenue: by Geography 2019
  • Figure 36. Lupin Pharmaceuticals, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 37. Lupin Pharmaceuticals, Inc. (India) Revenue: by Geography 2019
  • Figure 38. Global Bulimia Nervosa Treatment: by Therapy USD Million (2020-2025)
  • Figure 39. Global Bulimia Nervosa Treatment: by Drug type USD Million (2020-2025)
  • Figure 40. Global Bulimia Nervosa Treatment: by Route of administration USD Million (2020-2025)
  • Figure 41. Global Bulimia Nervosa Treatment: by End user USD Million (2020-2025)
  • Figure 42. Global Bulimia Nervosa Treatment: by Disorder type USD Million (2020-2025)
  • Figure 43. South America Bulimia Nervosa Treatment Share (%), by Country
  • Figure 44. Asia Pacific Bulimia Nervosa Treatment Share (%), by Country
  • Figure 45. Europe Bulimia Nervosa Treatment Share (%), by Country
  • Figure 46. MEA Bulimia Nervosa Treatment Share (%), by Country
  • Figure 47. North America Bulimia Nervosa Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Eli Lilly and Company (United States)
  • AstraZeneca (United Kingdom)
  • Forest Pharmaceuticals, Inc. (United States)
  • Pfizer, Inc. (United States)
  • Bristol-Myers Squibb (United States)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline (United Kingdom)
  • Allergan, Inc. (Ireland)
  • Dr. Reddy’s Laboratories Limited (India)
  • Lupin Pharmaceuticals, Inc. (India)
Additional players considered in the study are as follows:
Aurobindo Pharma (India) , Zydus Cadila (India) , Apotex Inc. (Canada) , Teva Pharmaceutical Industries Ltd (Israel) , Sun Pharmaceutical Industries Ltd (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation